GAI
APLS

General American Investors’s Apellis Pharmaceuticals APLS Stock Holding History

General American Investors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,000
Closed -$1.71M – 74
2023
Q3 		$1.71M Buy
+45,000
New +$1.98M 0.15% 62

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

General American Investors's APLS Position: Q4 2023 in Review

General American Investors sold out of Apellis Pharmaceuticals (APLS) in Q4 2023, closing a stake of 45,000 shares — an estimated $1.71M sold.

General American Investors first reported a position in APLS in Q3 2023 and held it in 1 quarter. The position peaked at $1.71M in Q3 2023. 283 funds tracked by Wall St. Rank hold APLS as of Q4 2023.

  • General American Investors reported no remaining Apellis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • General American Investors sold 45,000 Apellis Pharmaceuticals shares in Q4 2023, an estimated $1.71M.
  • General American Investors first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • General American Investors's Apellis Pharmaceuticals position peaked at $1.71M in Q3 2023.
  • 283 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2023.

Based on General American Investors's 13F filing for Q4 2023, filed 13 Feb 2024.